Teclistamab generated high response rates and deep minimal residual disease (MRD) negativity in patients with high-risk smouldering multiple myeloma, according to long-form results from the randomized phase II ImmunoPRISM study. The data position teclistamab as a potential disease-redirecting therapy earlier in the myeloma timeline. The report emphasizes complete response and MRD outcomes as key efficacy endpoints, aligning with the field’s broader push toward earlier intervention strategies to delay progression in patients at greatest risk.
Get the Daily Brief